Guest guest Posted December 17, 2006 Report Share Posted December 17, 2006 Hi Heidi Before I went to naturopathic college (so this is about 15 years ago), I worked with a Dr. , ND in Winnipeg, Manitoba. At the time I was doing volunteer work in his office trying to decide if being an ND was the career for me. As I recall, he had quite a few cancer and AIDs patients using 714X. I don't recall any " cured " cases, but I do remember people with large tumours or advanced disease doing extremely well as long as they continued the treatments. I believe he had patients inject themselves into an inguinal lymph node, and the 714x was supplied under a special drug release program by the Canadian government. That is all I can remember, but you may be able to find Dr. 's number listed somewhere and call him for more information. I believe he is still practicing in Manitoba. Loreen Dawson, ND Sechelt, BC Family Medicine Quoting Heidi Mayer RNCP <hdm4wellness@...>: > Here is a start. I am going on Holidays until early in the New Year. Be back > with an update on how my client is doing on 714-X...She is currently doing > all of the BTG's,,using HMF replete and doing fine so far. > Season's Greetings to all!! > Sincerely, > Heidi Mayer B.Sc. RNCP > Clinical Nutritionist > > Cancer patients highlight new 714X controversy and the NCI agrees > to review the treatment > > © By Chowka > (June 1, 2001) A small but dedicated group of cancer patient activists in > Eastern Massachusetts has helped to bring to light what they describe as a > possible cover-up of promising, preliminary test results of 714X, a > controversial unconventional cancer treatment from Canada, at the prestigious > Dana-Farber Cancer Institute in Boston. A subsequent avalanche of media > reporting about the story in the Boston area has resulted in Dana-Farber on > May 21 calling on the National Cancer Institute (NCI) to undertake a formal > review of 714X, which the NCI's Office of Cancer Complementary and > Alternative Medicine (OCCAM) has agreed to do. > The case is unique: patients decry a cover up of a promising alternative > treatment and the cancer establishment responds almost immediately by > promising to review it. The whole episode illustrates the impact that people > with cancer, highly motivated and using tools such as the media and the > Internet, can have on getting alternative therapies tested at the highest > levels of the federal government. And it suggests that a climate of openness > is replacing the closed mindedness of the past in terms of national cancer > policy. > Key players in the still developing story include cancer patients Cheryl > Cavallo and Best and 's parents, Sue and Bill Best, and OCCAM > director White, MD. > Best, WCVB-TV, May 2001 Best, 23, gained major national > attention in 1994 when he ran away from home rather than continue to take > chemotherapy for his Hodgkin's Disease. Coaxed by his parents to return to > their home in a suburb south of Boston, Best chose two alternative therapies, > 714X and another unconventional Canadian treatment, the herbal compound > Essiac. Best was supported in his decision by his parents and by a state > court, which found in 1995 that, at age 16 1/2, he was old enough to make up > his own mind about his treatment options. (Dana-Farber had reported the Best > family to the state's Department of Social Services for legal action when it > was learned that the young man was taking 714X.) Seven years later now, Best > says he is cancer free. Since the mid-1990s, Best and his parents have > provided information about alternatives to many people with cancer in > Massachusetts and around the country. > > 714X > 714X is a nontoxic, relatively inexpensive alternative cancer therapy > developed by " researcher-biologist " Gaston Naessens. Its chemical name is > trimethylbicyclonitramineoheptane chloride. Gaston Naessens, > WFXT-TV, May 2001 > According to a technical file at the Web site of Cerbe Inc., the Canadian > company that manufactures and distributes it, 714X " contains nitrogen as its > primary ingredient, camphor as its vehicle, mineral salts and 18 trace > elements. " It is available in both injectible and inhalable forms of > administration. The Cerbe file goes on, " 714X is a product created to improve > health by revitalizing the immune system and is not designed to act directly > on disease releated sysmptoms. 714X supports natural defenses (including the > immune system) when introduced into the lymphatic circulation. " The Center > for Alternative Medicine Research in Cancer at the University of Texas at > Houston (UTH) describes its mechanism of action as follows: " 714X is a > derivative of camphor with an extra nitrogen molecule attached. > Theoretically, 714X supplies the body with the nitrogen it needs to > neutralize the nitrogen hungry tumor cells and stops cancer cells from > producing CKF. Naessens believes that if > the CKF substance is neutralized, the immune system will be able to > recognize cancer cells as foreign entities and attack them. 714X also > contains organic salts which fluidify the lymph to carry away the toxins > accumulated during the illness. 714X is reportedly nontoxic. . .Naessens > recommends that cancer patients adopt a largely whole grain, vegetable, and > fruit diet with small amounts of meat as needed. " > Like most proponents of alternative cancer therapies, credentialed or not > (Naessens has no medical or advanced scientific degrees), Naessens has been > surrounded by controversy since he began his career as a medical innovator > and inventor in his native France in the 1950s. He moved to Quebec, Canada in > the early 1970s. In 1989, he was tried in Canada for practicing medicine > without a license but acquitted by a jury. The UTH Center reported in 1999 > that 714X, developed in the 1970s, " has been legalized by the Canadian > government and over 800 physicians are using this therapy for patients. . > .Volume of sales is rising per COSE (7/8/96); the cost of treatment is > inexpensive in Canada and usually covered by insurance; costs are $50 for 21 > days and usually continued for 3 month intervals. " 714X is also widely used > in Japan. In the U.S., individual patients may legally import supplies of > 714X directly from Cerbe for their personal use. In 2001, according to the > Cerbe Web site, > the cost in U.S. dollars of a 21 day supply of injectible 714X was $300. > Supporters of Naessens depict him as a world class original mind. The title > of a 1991 biography by the late Bird, The Galileo of the > Microscope, refers to Naessens' development of a high resolution dark field > microscope with magnification of 30,000X that allows examination of live > blood. > > > The Massachusetts Patients Expose an Apparent Cover-up > Cheryl Cavallo, WBZ-TV, May 2001 Cheryl Cavallo of Pembroke, MA, > 39, married and the mother of two children, was diagnosed with breast cancer > in 1997. Despite following an aggressive conventional protocol that included > a lumpectomy, a mastectomy, radiation, chemotherapy, and hormone treatments > at the Dana-Farber Cancer Institute in Boston, Cavallo's cancer spread to her > spine. In May 2000 she discontinued conventional treatments and concentrated > on alternative therapies, including diet and Essiac. In September 2000 she > started taking 714X. > In an interview on May 30, Cavallo said that she was influenced to start > taking 714X when she read some of the sealed records of a court case > involving Cerbe, the Canadian company that manufactures and distributes 714X, > and Dana-Farber. The documents were brought to light by Sue Best in the > summer of 2000. The court case related to a test of 714X that Cerbe hired > Dana-Farber researchers to conduct in 1999. In a letter written August 9, > 1999 to Dana-Farber's Director of Research that has since been leaked to the > media, one of the researchers involved in the 714X test, Dr. Arthur B. > Pardee, professor at Dana-Farber's Division of Cancer Biology, and Lili > Huang, his research associate, wrote " For the first time, our data provide > scientific evidence supporting that 714X is an immune stimulus. . .714X is > thought to elevate the immune response and have some role in killing tumor > cells. Our data provide evidence to support this theory. " Pardee and Huang > added, according to the > Boston Herald (May 21, 2001), that their preliminary " test results 'clearly > demonstrate' that 714X activates white blood cells and induces the secretion > of proteins that play a role in the body's immune defense system, including > the part of the immune system that recognizes tumor cells. " A Dana-Farber > official, Chuck Stiles, vice chairman of the cancer biology department, > replied to the Pardee-Huang letter on April 19, 1999: " I am very worried > about this work. " > Shortly after the 714X tests began in 1999, the promise of the early > results notwithstanding, they were shut down by Dana-Farber. Cerbe then sued > Dana-Farber for breach of contract, alleging that, althought the tests showed > " positive chemokine reactivity " for 714X, Dana-Farber peremptorily ended the > tests. In the suit, Cerbe sought the return of the 714X samples it had > provided to Dana-Farber as well as the test results. The suit was settled out > of court in mid-2000 and a confidentiality agreement prohibits both parties > from discussing the case. Nothing prevented Sue Best from publicizing the > case, however (in the intervening years she has developed a relationship with > Cerbe and Naessens and she saw copies of the court documents). In mid-2000 > she began sharing the news about the lawsuit and e-mailing and calling the > media with the story. > > The Media Play a Role > WFXT TV reporter-anchor Steve Aveson > introduces Fox Undercover report on 714X, > May 14, 2001 > During the winter of 2000-2001, Boston's NBC TV affiliate WHDH channel 7 > prepared a report on the 714x-Cerbe-Dana-Farber story including interviews > with Cavallo, the Bests, and others. It never aired. (Cavallo and Sue Best > allege that they were told by a reporter that someone in the station's upper > management or possibly even the owner deep-sixed the story.) At that point, > Sue Best began contacting other media and found interest at Boston's upstart > Fox network TV channel, WFXT 25, which airs an hour of local news in prime > time nightly at 10 pm. (Boston currently has a very competitive TV news > environment.) After an article in the Boston Herald on April 2 and brief > reports on the 11 pm news by WBZ TV channel 4 on May 1 set the stage, WFXT as > part of its " Fox Undercover " series aired two segments about the 714X story > on May 14 - unprecedented in length, depth, and quality for a local newscast. > The report was titled " Canadian Cancer Cure. " In introducing the segments, > Steve > Aveson, the newscast's co-anchor who also reported the story, said, " There > are some patients who feel that the [Dana-Farber] Institute is keeping some > of its best research a secret. . .Fox Undercover investigates why this > Canadian cancer cure is banned in Boston. " > WFXT interviewed Best, Cavallo, and Hartley, 14, another cancer > patient who has used 714X and is now cancer free, according to her mother > Hartley. The segments also featured reporting from Canada and an > interview with Naessens. Through a translator, Naessens said 714X " permits > the natural defenses to be strong and healthy and then the body can itself > fight against disease. " The report prominently mentioned the positive results > of the preliminary 714X tests at Dana-Farber, the sudden termination of the > tests, and the Cerbe-Dana-Farber lawsuit. Naessens said that " Anything that > comes - that is not actually the brainchild of the drug industry is being > criticized and is being pushed aside. " > The report included comments by a critic of 714X, Rosenthal, MD, past > president of the American Cancer Society and currently the head of the Lenny > Zakim Center for Integrated Therapies at Dana-Farber. Rosenthal would not > comment directly on Dana-Farber's tests of 714X but he said in answer to a > question about Naessens " He's been in jail twice; why has he been in jail > twice? " Reporter Aveson observed in a voice-over that Naessens has not been > in jail twice although he has been fined several times for practicing > medicine without a license. > The next night, May 15, apparently due to intense viewer interest, the WFXT > 10 pm news repeated about one half of the previous evening's 714X feature. > Another report led the WFXT 10 pm newscast on May 21. Boston stations WBZ > (CBS, channel 4) and WCVB (ABC, channel 5) broadcast their own feature > reports (on May 22 and 29 respectively), the Herald printed three more > stories (on May 21 and 23), and the high circulation suburban daily The > Patriot-Ledger ran a feature on May 23. All of the reporting was at least > objective and, in some cases, could be interpreted as casting positive light > on 714X. Virtually all of the articles and TV reports prominently featured > Cavallo, who, despite her ongoing battle with cancer, always appeared > energetic, healthy, and articulate. She, and Best, who was also widely > interviewed and usually shown riding his skateboard, were compelling > advocates for 714X. The fact that 714X appeared to be the victim of actions > by Dana-Farber (the summary > cessation of the 1999 tests) that were suspicious at best added a hook and, > in broadcasting industry parlance, gave the story " legs. " > > The NCI is Called In > Apparently, public pressure on the media and on Dana-Farber accelerated and > on May 21 it was learned that Dana-Farber had requested that the NCI conduct > a test of 714X and that the NCI had agreed. Cerbe issued a statement that > said " We are willing to work with the NCI immediately. " According to media > reports, including the Patriot-Ledger story on May 23, Dana-Farber asked for > the review. According to Dana-Farber spokesman Singer, the call to the > NCI went out " because we started getting a lot of questions from patients > about 714X " after publicity on the drug. Singer added, " This stuff is out > there being promoted to the general public as a cancer drug. While we've seen > no scientific evidence (that it works), we think it makes sense for the NCI > to determine if the compound merits further study. " DeWaele, > assistant to Cerbe's president, told the Patriot-Ledger that the company has > records for hundreds of patients, and added " We're just chomping at the bit > [to > have the drug reviewed]. " > In the past, when disputes involving testing of alternative cancer > therapies at mainstream institutions came to light, the institutions would > typically circle the wagons, dig in, and continue to cover up. In the view of > many independent observers, such was the case when Memorial Sloan-Kettering > Cancer Center in New York tested the controversial substance laetrile in the > mid-1970s. These days, things have changed quite a bit and there are other > options, including, in the case of 714X, sending the whole issue down to the > National Cancer Institute. > > White, MD > White, MD > ABC World News Tonight > June 9, 2000 Since 1999, the NCI has had an Office of Cancer Complementary > and Alternative Medicine (OCCAM). It works closely with the National Center > for Complementary Alternative Medicine (NCCAM). OCCAM's director, > White, MD, has a reputation as a fair and open-minded administrator. In 2000, > White publicly defended , MD when there was criticism of the > New York City clinician for being awarded a $1.4 million government grant to > test an unconventional enzyme-nutrition therapy on pancreatic cancer. > In a telephone interview on May 30, White told me how the NCI review of > 714X is expected to go forward. " We agreed to put out a request for patient > case report information through our best case series program, " he explained. > " We've contacted the company in Canada, Cerbe, and sent a letter to Mr. > Naessens. Actually, we've already received a response from [Naessens] > expressing willingness to provide us the information. Hopefully, we will > receive [the information] and take a look at it. " > White said that the review of 714X would be different, for example, than > the review of case histories of the Bio-Medical Center in Tijuana, Mexico > (Hoxsey Therapy) and the Livingston-Wheeler clinic in San Diego that were > financially supported by the government but conducted by the University of > Texas at Houston and published this past February. The NCI's review of 714X > will be done in-house. > According to White, " The [714X] review is done at the NIH's clinical > center. We have members in the pathology department there, in the radiology > department, that review the films and the path slides for us. We do have an > established best case series process and that's what we're trying to > implement here. The differences are that we've not dealt directly with a > company before to obtain data. We normally deal with a practitioner who has a > group of patients that he or she has treated and we deal directly with them. > So what we've asked the company [Cerbe] to do is to either obtain the data > for us on patients they know have received the 714X or to contact physicians > that they know have used this and ask them to supply the information. That's > one difference. But basically we'll be asking for exactly the same material: > copies of pathology reports, copies of radiographic reports. Then we'll > review the actual pathology slides and the actual radiographic films. " > I asked White if there is a minimum number of 714X case histories required > before some kind of conclusions can be reached. " Well, we have generally > asked for at least four or five cases. . .It's not 100 cases. . .We'd like to > see a reasonable number of high quality cases. But if it's ten cases, that > would be fine. " > As far as the time line, White said that Cerbe " did tell me that they're > going to try to get me this information by the middle of August. I try not to > hold people to those kinds of things because once they get into the process > they find out how difficult it may be, but that's what they're shooting for. > If they're able to do that - and again, this is going to depend on the number > of cases - if it's about ten cases or something like that, then we ought to > be able to get that review done in a month's time. Then we'll have to find > out when the next meeting of the CAPCAM - the Cancer Advisory Panel for > Complementary Alternative Medicine- is and get it [714X] scheduled on the > agenda for CAPCAM review. > " [CAPCAM] will have seen copies of the reports or at least a summary of the > data. And then the individual cases will be discussed at the meeting, case by > case. And they [CAPCAM panel members] will make their analysis of each case. > We don't put forward case series that we don't think - that they are going to > just say are garbage (laughs), unless there's some compelling reason for us > to do that. And I would prefer not to waste time with that. . . We're still > going to make every effort we can to get the best case series. " > I asked White about the process that comes after the CAPCAM panel's review > of the data, assuming it is positive. > " What the panel would do, if they feel that it's adequate information for > them to determine if . . .there's some suggestive activity here or something > that needs to be followed up, then they would make a recommendation to the > director of of NCCAM [the National Center for Complementary and Alternative > Medicine] that NCCAM ought to support research in that area. They may > specifically say what kind of research they are talking about - clinical > trial of some type or they can be as specific as they want to about that. And > then, if that is the recommendation, it's up to NCCAM to act on it within > their other priority areas. If this is something that they also consider to > be - that they have the resources to deal with, then they'll work with NCI to > figure out the appropriate mechanism. " > I asked White if in fact Dana-Farber had asked the NCI to review 714X and, > if that was the case, if it was an unusual request. He replied, " Yes. We've > not been approached by a cancer center before to investigate something like > this. We actually just recently in the past seven or eight months started to > advertise the existence of the best case series program. So a lot of people > don't know that we actually do it. The contacts that we've gotten so far have > come generally from individual practitioners. But, yes, this is relatively > unique that we that we have a cancer center recommending that we investigate > this. . . > " I'm glad that we're getting an opportunity to take a look at it, " he > added. " We've certainly received already calls from patients that feel that > they've benefited from this approach. " > > For more information, > Office of Cancer Complementary and Alternative Medicine NCI > > Friends with Hope (Cheryl Cavallo) > > and Sue Best > > Cerbe Distribution > > Cerbe technical data on 714X (PDF) > > The Center for Alternative Medicine Research in Cancer at the University of > Texas - 714X summary > > The Center for Alternative Medicine Research in Cancer at the University of > Texas - 714X detailed information > > > Boston media reports > Boston Herald, April 2 > > WBZ TV, May 1 and 22 > WFXT TV, May 14 > > Boston Herald, May 21 > Boston Herald, May 21 > > Boston Herald, May 23 > > The Patriot-Ledger, May 23 > > WCVB TV, May 29 > > > Home > __________________________________________________ > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted February 7, 2011 Report Share Posted February 7, 2011 Hello, A friend of mine just talked to me about a product called 714-X. Has anyone heard of this or used it? Yannick Quote Link to comment Share on other sites More sharing options...
Guest guest Posted February 7, 2011 Report Share Posted February 7, 2011 interesting. developed in canada i think: Â http://www.encognitive.com/node/2437 From: cancfs <ambitious8@...> Subject: 714-X Received: Monday, February 7, 2011, 1:30 PM Â Hello, A friend of mine just talked to me about a product called 714-X. Has anyone heard of this or used it? Yannick Quote Link to comment Share on other sites More sharing options...
Guest guest Posted February 9, 2011 Report Share Posted February 9, 2011 I actually knew someone who flew with her daughter to Canada for the treatment but I'm not sure how it turned out and it's been like 10-15 years ago. I think you have to inject the drug into a lymph node. Kendra On Tue, Feb 8, 2011 at 12:21 PM, RoosterRick <rickstr420@...> wrote: > Sounds a little far fetched.......Somatids??? > > 714-X was developed by Gaston Naessens, a native of France who has lived and worked in Quebec since the early 1970s. The name " 714-X " was chosen by Naessens to symbolize his initials (the 7th and 14th letters of the alphabet) and the year of his birth (1924, as X is the 24th letter).[2] The marketers claim that 714-X works by counteracting the harm done by " somatids " , a fictional life form which is not bacterial, viral or fungal, but which instead belongs to a distinct domain unknown to modern science and medicine.[3] > >> >> Hello, >> A friend of mine just talked to me about a product called 714-X. >> Has anyone heard of this or used it? >> >> Yannick Quote Link to comment Share on other sites More sharing options...
Guest guest Posted February 9, 2011 Report Share Posted February 9, 2011 Hello, Thank you all for the replies. I am aware of what is on the internet regarding 714-X. What I was asking is whether anyone on this forum has ever used 714-X or known someone who has used it. I am interested in hearing personal experiences with 714-X...not what is on the internet. Yannick > > > > Hello, > > > > A friend of mine just talked to me about a product called 714-X. > > > > Has anyone heard of this or used it? > > > > Yannick > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted February 10, 2011 Report Share Posted February 10, 2011 Dear Rick Whatever the failings of Gustav Naessens, the scientific community is well aware of nanobacteria and nannobes (maybe two different entities) See http://en.wikipedia.org/wiki/Nanobe on the work of Philippa Uwins If there are failings it is in the establishment having closed minds about new evidence Regards R Re: 714-X > Sounds a little far fetched.......Somatids??? > > 714-X was developed by Gaston Naessens, a native of France who has lived > and worked in Quebec since the early 1970s. The name " 714-X " was chosen by > Naessens to symbolize his initials (the 7th and 14th letters of the > alphabet) and the year of his birth (1924, as X is the 24th letter).[2] > The marketers claim that 714-X works by counteracting the harm done by > " somatids " , a fictional life form which is not bacterial, viral or fungal, > but which instead belongs to a distinct domain unknown to modern science > and medicine.[3] > > > > > > >> >> Hello, >> >> A friend of mine just talked to me about a product called 714-X. >> >> Has anyone heard of this or used it? >> >> Yannick >> > > > > > ------------------------------------ > > This list is intended for patients to share personal experiences with each > other, not to give medical advice. If you are interested in any treatment > discussed here, please consult your doctor. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.